2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Sunday, November 13, 2016

9:00AM-11:00AM: Abstract Number: 425

Improving Pneumococcal Vaccination Rates for Immunosuppressed Patients in an Academic Rheumatology Clinic

Quality Measures and Quality of Care - Poster I

9:00AM-11:00AM: Abstract Number: 699

In Contrast to Men, Women with Nonradiographic Axial Spondyloarthritis Have Lower Response Rates to TNF Inhibitors Than Women with Ankylosing Spondylitis

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster I: Axial and Peripheral Spondyloarthritis – Clinical Aspects, Imaging and Treatment

9:00AM-11:00AM: Abstract Number: 701

In Patients with Ankylosing Spondylitis Treated with Adalimumab, Combination Therapy with DMARD, Increase the Serum Level of Adalimumab and Decrease Immunogenicity

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster I: Axial and Peripheral Spondyloarthritis – Clinical Aspects, Imaging and Treatment

9:00AM-11:00AM: Abstract Number: 275

In Vitro Activation of Type I Interferon Pathway Reproduces the Characteristics Damages Observed in Dermatomyositis Patients

Muscle Biology, Myositis and Myopathies - Poster I: Basic/Translational

9:00AM-11:00AM: Abstract Number: 227

Inadequately Treated Chronic Gout As the Main Reason for Primary Gout Admission in an Urban Adult Population: Results of a Retrospective Cohort Study

Metabolic and Crystal Arthropathies - Poster I: Clinical Practice

9:00AM-11:00AM: Abstract Number: 22

Incidence and Factors Associated with the Development of Non Alcoholic Fatty Liver Disease(NAFLD) Among Patients with Rheumatoid Arthritis

Epidemiology and Public Health - Poster I

9:00AM-11:00AM: Abstract Number: 437

Incidence of Gastrointestinal Events and Physician Compliance of Co-Prescribing Proton Pump Inhibitors in Chronic NSAID Users with Osteoarthritis, Rheumatoid Arthritis and Ankylosing Spondylitis

Quality Measures and Quality of Care - Poster I

9:00AM-11:00AM: Abstract Number: 700

Incidence of Inflammatory Bowel Disease Events in Adalimumab (HUMIRA) Clinical Trials Across Indications

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster I: Axial and Peripheral Spondyloarthritis – Clinical Aspects, Imaging and Treatment

9:00AM-11:00AM: Abstract Number: 23

Incidence of Non Alcoholic Fatty Liver Disease By Key Risk Factors Among Patients with Rheumatoid Arthritis

Epidemiology and Public Health - Poster I

9:00AM-11:00AM: Abstract Number: 895

Incidence of Osteoporotic Mayor Fractures in a Cohort of Patients with Polymyalgia Rheumatica

Vasculitis - Poster I: Large Vessel Vasculitis and Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 319

Incident Participation Restriction in Adults with Knee Osteoarthritis: Do Positive and Negative Affect Matter? the Multicenter Osteoarthritis Study

Osteoarthritis – Clinical Aspects - ARHP Poster

9:00AM-11:00AM: Abstract Number: 690

Increase in Serum Leptin Levels Is Associated with Radiographic Progression of Male Patients with Ankylosing Spondylitis: A 2-Year Longitudinal Study

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster I: Axial and Peripheral Spondyloarthritis – Clinical Aspects, Imaging and Treatment

9:00AM-11:00AM: Abstract Number: 280

Increased Expression of TIF-1 Gamma in Duodenal Adenocarcinoma from a Patient with p155/140 Dermatomyositis: A Causal Relationship?

Muscle Biology, Myositis and Myopathies - Poster I: Basic/Translational

9:00AM-11:00AM: Abstract Number: 62

Increased Frequency of Anti-Drug Antibodies in Patients Carrying Compatible IgG1 Allotypes and Treated with Anti-TNF Antibodies

Genetics, Genomics and Proteomics - Poster I

9:00AM-11:00AM: Abstract Number: 279

Increased Heat Shock Protein 90 in Muscle Tissue and Plasma in Idiopathic Inflammatory Myopathies Correlates with Disease Activity and Skeletal Muscle Involvement

Muscle Biology, Myositis and Myopathies - Poster I: Basic/Translational

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].